Clinical trials
Recent articles
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Year in Review: Spectrum’s best in 2023
Here are five must-reads from our coverage of autism research over the past 12 months.
Year in Review: Spectrum’s best in 2023
Here are five must-reads from our coverage of autism research over the past 12 months.
Standout neuroscience news in 2023
Did you miss any of our favorite stories from the past year? Revisit them here.
Standout neuroscience news in 2023
Did you miss any of our favorite stories from the past year? Revisit them here.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Explore more from The Transmitter
Expanding set of viral tools targets almost any brain cell type
Harmless viruses that encase short noncoding DNA elements called enhancers enable cell-type-specific gene delivery across the central nervous system in rodents and primates.
Expanding set of viral tools targets almost any brain cell type
Harmless viruses that encase short noncoding DNA elements called enhancers enable cell-type-specific gene delivery across the central nervous system in rodents and primates.
Executive function; screen time; Rett syndrome therapy
Here is a roundup of autism-related news and research spotted around the web for the week of 18 November.
Executive function; screen time; Rett syndrome therapy
Here is a roundup of autism-related news and research spotted around the web for the week of 18 November.
Premature declarations on animal consciousness hinder progress
Overstating the evidence in support of animal consciousness could impede efforts to develop more accurate ways of assessing it.
Premature declarations on animal consciousness hinder progress
Overstating the evidence in support of animal consciousness could impede efforts to develop more accurate ways of assessing it.